Management of atrial fibrillation: direct factor IIa and Xa inhibitors or "warfarin shotgun"?

J. Halperin,R. E. Goyette

Published 2012 in The Mount Sinai journal of medicine, New York

ABSTRACT

No abstract is available for this paper.

PUBLICATION RECORD

Publication year
2012
Venue
The Mount Sinai journal of medicine, New York
Publication date
2012-11-01
Fields of study
Medicine
Identifiers
DOI 10.1002/msj.21346 PMID 23239209
External record
Open on Semantic Scholar
Source metadata
Semantic Scholar, PubMed

CITATION MAP

EXTRACTION MAP

CLAIMS

No claims are published for this paper.

CONCEPTS

No concepts are published for this paper.

REFERENCES

New oral anticoagulants
2013cited by this paper
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
2012cited by this paper
New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
2012cited by this paper
Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
2012cited by this paper
Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
2012cited by this paper
Bleeding risk with dabigatran in the frail elderly.
2012cited by this paper
Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
2012cited by this paper
Erratum: utilization of anticoagulation therapy in medicare patients with nonvalvular atrial fibrillation.
2012cited by this paper
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban
2012cited by this paper
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.
2012cited by this paper
Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry.
2012cited by this paper
Dabigatran-Induced Gastrointestinal Bleeding in an Elderly Patient with Moderate Renal Impairment
2012cited by this paper
Apixaban in patients with atrial fibrillation.
2011cited by this paper
Low molecular weight heparin versus unfractionated heparin for thromboprophylaxis in patients with acute atrial fibrillation: A randomized control trial
2011cited by this paper
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
2011cited by this paper
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis.
2011cited by this paper
Apixaban versus warfarin in patients with atrial fibrillation.
2011cited by this paper
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
2011cited by this paper
Laboratory assessment of new anticoagulants
2011cited by this paper
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
2011cited by this paper
Hemostatic Therapy in Experimental Intracerebral Hemorrhage Associated With the Direct Thrombin Inhibitor Dabigatran
2011cited by this paper
Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers
2011cited by this paper
Early Heparin Administration Reduces Risk for Left Atrial Thrombus Formation during Atrial Fibrillation Ablation Procedures
2011cited by this paper
Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects
2011cited by this paper
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty
2011cited by this paper
Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
2011cited by this paper
Low Concentrations of rhFVIIa or FEIBA Significantly and Rapidly Reverse the Anticoagulant Effects of Supratherapeutic Edoxaban
2011cited by this paper
All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation
2011cited by this paper
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
2011cited by this paper
The Successful Reversal of Dabigatran-Induced Bleeding by Coagulation Factor Concentrates in a Rat Tail Bleeding Model Do Not Correlate with Ex Vivo Markers of Anticoagulation
2011cited by this paper
New oral anticoagulants
2011cited by this paper
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
2010cited by this paper
Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial
2010cited by this paper
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
2010cited by this paper
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
2010cited by this paper
Evidence‐based practice guidelines for plasma transfusion
2010cited by this paper
Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
2010cited by this paper
Effect of Prothrombin Complex Concentrate on Hematoma Enlargement and Clinical Outcome in Patients with Anticoagulant-Associated Intracerebral Hemorrhage
2010cited by this paper
Use of recombinant factor VIIa in US military casualties for a five-year period.
2010cited by this paper
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
2010cited by this paper
New anticoagulants and the future of cardiology.
2010cited by this paper
Prothrombin complex concentrates: an update.
2010cited by this paper
Los nuevos anticoagulantes y el futuro de la cardiología
2010cited by this paper
Newly identified events in the RE-LY trial.
2010cited by this paper
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
2010cited by this paper
Suboptimal effect of a three‐factor prothrombin complex concentrate (Profilnine‐SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose
2009cited by this paper
Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy
2009cited by this paper
Atrial fibrillation and anticoagulation in a stroke unit population
2009cited by this paper
Dabigatran versus warfarin in patients with atrial fibrillation.
2009cited by this paper
Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation
2009cited by this paper
Blood Coagulation: Hemostasis and Thrombin Regulation
2009cited by this paper
Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related factors.
2008cited by this paper
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
2008cited by this paper
Mechanisms of thrombus formation.
2008cited by this paper
Venous Thromboembolism : Mechanisms , Treatment , and Public Awareness
2008cited by this paper
The management of non-valvular atrial fibrillation (NVAF) in Australian general practice: bridging the evidence-practice gap. A national, representative postal survey
2008cited by this paper
Clinical Epidemiology of Atrial Fibrillation and Related Cerebrovascular Events in the United States
2008cited by this paper
New Anticoagulants for Treatment of Venous Thromboembolism
2008cited by this paper
Warfarin resistance.
2008cited by this paper
Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V.
2007cited by this paper
Death and disability from warfarin-associated intracranial and extracranial hemorrhages.
2007cited by this paper
Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion.
2007cited by this paper
Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation.
2007cited by this paper
Fresh frozen plasma transfusion in critically ill patients*
2007cited by this paper
Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF).
2007cited by this paper
Direct Thrombin Inhibition and Stroke Prevention in Elderly Patients With Atrial Fibrillation: Experience From the SPORTIF III and V Trials
2007cited by this paper
Warfarin use in the elderly: the nurses' perspective.
2006cited by this paper
Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence
2006cited by this paper
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text
2006cited by this paper
Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation.
2006cited by this paper
Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis.
2006cited by this paper
Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study).
2006cited by this paper
Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation
2005cited by this paper
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
2005cited by this paper
Are Cost Benefits of Anticoagulation for Stroke Prevention in Atrial Fibrillation Underestimated?
2005cited by this paper
Predictors of new-onset kidney disease in a community-based population.
2004cited by this paper
Factor Xa inhibitors
2004cited by this paper
Over-the-counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients
2004cited by this paper
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
2003cited by this paper
Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded.
2003cited by this paper
Mechanism of action of recombinant factor VIIa
2003cited by this paper
A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.
2002cited by this paper
A comparison of rate control and rhythm control in patients with atrial fibrillation.
2002cited by this paper
Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting.
2001cited by this paper
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.
2001cited by this paper
Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
2001cited by this paper
Recombinant factor VIIa (Novoseven) restores deficient coagulation: experience from an ex vivo model.
2001cited by this paper
Why do patients with atrial fibrillation not receive warfarin?
2000cited by this paper
Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
2000cited by this paper
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
1999cited by this paper
Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
1998cited by this paper
Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic Warfarin therapy
1997cited by this paper

CITED BY